AstraZenica CEO quits after drug sales slump
Quote of the day: 'After more than six years as chief executive officer of this great company I have decided that now is the right time to step down and allow a new leader to take the reins.' David Brennan has abruptly quit as AstraZenica chief exec after investors voiced their discontent in a boardroom coup. Underlying profits at the drug-maker fell 19% in the first quarter of 2012, causing the share price to drop by 3.5% this morning. Brennan's shock departure has forced the board to scramble for an interim CEO; chief financial officer Simon Lowth is stepping into the breach while a permanent successor is found.